May 18, 2025, 00:51

CANSA Type A Research Funding Programme

The CANSA Type A Research Grant funds research that contributes to cancer control in South Africa across a wide spectrum of topics, including epidemiology, health-seeking behaviour, early detection, treatment, health systems strengthening, and health economics. Research on cancer biology and molecular mechanisms is also eligible if tied to risk reduction, detection, or care.

Eligibility Criteria:

Open to South African citizens or permanent residents only
Must be an independent researcher, preferably with a PhD
Clinical researchers with an MBChB and proven publication record are also eligible
Master’s-level researchers may apply under supervision of a PhD-qualified PI
Only one application per applicant per year; only one active grant at a time
PI must be based full-time (80% minimum) in South Africa
Research must be conducted at an accredited South African research institution
Research Ethics approval is required before funds are released

Funding Details:

Up to ZAR 1,000,000 annually for three years
CANSA contributes 75% (ZAR 750,000), and the institution must contribute 25% (ZAR 250,000) per year
Grants cover salaries (max 15%), equipment, research assistants, travel (max ZAR 25,000/year for conferences), collaborator visits (max ZAR 15,000/year), publication costs (max ZAR 40,000), and other project-specific expenses
Indirect costs limited to 14%
At least three ISI-accredited publications are expected within four years

Deadline:

Full proposals due: 30 September
Notifications of award: December

Where to Apply / Learn More:

CANSA Website

Cancer Control Cancer research CANSA early detection epidemiology funding call health services health systems molecular biology Oncology Palliative Care prevention public health research grant South Africa Type A grant

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial

New World Cancer Declaration 2025–2035 by UICC

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that